- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT01144988
Avastin / Irinotecan in Patients With Recurrent or Progressive Malignant Glioma (AVIRMA01-09)
An Academic Prospective Single-arm Phase II Clinical Trial for Evaluation of Advanced Functional Neuroimaging Techniques and Molecular Markers in the Course of Anti-angiogenic Therapies in Malignant Gliomas
Malignant glioma are the most common and aggressive primary brain tumors in adults. Despite advances in multimodal treatment including surgery, radiation and chemotherapy, most patients have a dismal prognosis of 9-15 months (Stupp et al., NEJM 2005).
A major reason for the aggressiveness of malignant glioma is a pronounced tumor neovascularization, mainly driven by the vascular endothelial growth factor (VEGF) and its receptors. The therapeutic monoclonal antibody Bevacizumab (Avastin®) inhibits the VEGF pathway by binding the VEGF ligand. In Magnetic Resonance Imaging (MRI) this treatment reduces contrast enhancement by restoring both, the blood-brain-barrier and the destabilized vessel integrity. Furthermore, it raises the sensitivity of co-administered chemotherapeutics such as Irinotecan. In conclusion, anti-angiogenic therapy leads to the problem that the routinely used MRI techniques cannot distinguish anti-vascular effects from true anti-tumor effects.
The study hypothesis of the clinical trial part is that in 35% of malignant glioma patients Avastin / Irinotecan chemotherapy results in objective tumor responses assessed by standard / functional MRI and FET- /FLT-PET neuroimaging. The study hypothesis for the translational study part is that the expression of the molecular targets of Avastin and Irinotecan in malignant glioma tissue ( = tumor and vascular cells) are predictive for Avastin / Irinotecan therapy induced treatment response measured by functional MRI and FET- / FLT-PET imaging.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Studientyp
Einschreibung (Voraussichtlich)
Phase
- Phase 2
Kontakte und Standorte
Studienkontakt
- Name: Guenther Stockhammer, MD, Prof.
- E-Mail: guenther.stockhammer@i-med.ac.at
Studieren Sie die Kontaktsicherung
- Name: Markus Hutterer, MD
- E-Mail: m.hutterer@salk.at
Studienorte
-
-
-
Innsbruck, Österreich, A-6020
- Rekrutierung
- Medical University Innsbruck, Department for Neurology
-
Kontakt:
- Guenther Stockhammer, MD, Prof.
- E-Mail: guenther.stockhammer@i-med.ac.at
-
Kontakt:
- Martha Nowosielski, MD
- E-Mail: Martha.Nowosielski@i-med.ac.at
-
Hauptermittler:
- Guenther Stockhammer, MD, Prof.
-
Unterermittler:
- Martha Nowosielski, MD
-
Unterermittler:
- Markus Glatzer, MD
-
Salzburg, Österreich, 5020
- Rekrutierung
- Paracelsus Medical University, Christian Doppler Klinik
-
Kontakt:
- Markus Hutterer, MD
- E-Mail: m.hutterer@salk.at
-
Hauptermittler:
- Stefan Golaszewski, MD
-
Unterermittler:
- Markus Hutterer, MD
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Patients present with a first or second tumor recurrence / progression of a histological confirmed supratentorial malignant glioma WHO Grade III-IV (Classification following WHO criteria).
Patients with surgical resection of tumor recurrence / progression: Following standard therapy(first recurrence) or standard therapy / second line chemotherapy (second recurrence, excepting antiangiogenic approaches) patients must have evidence of further tumor progression measured by standard MRI sequences (MacDonald criteria). If possible, patients may have prior surgical resection of the tumor progression and will be eligible if the following conditions apply:
- Patients must have recovered from the effects of surgery
- To adequately asses the malignant glioma before surgery and the extent of residual disease postoperatively, two MRIs scans have to be performed:
- A first standard MRI scan has to be done within 1 week before surgery to document a progressed or recurrent malignant glioma.
- A second standard / functional MRI scan has to be done between 24 and 48 hours after surgery to document the postoperative malignant glioma (Baseline MRI scan).
- FET- / FLT-PET scans have to be done within 2 weeks after surgery to document the postoperative malignant glioma (Baseline PET scans).
Patients without surgical resection of the tumor recurrence / progression: Patients must have evidence of tumor progression measured by standard MRI sequences (MacDonald criteria).
- Additional functional MRI sequences have to be done within 1 week prior to study enrollment.
- FET- / FLT-PET scans have to be done within 2 weeks after surgery to document the postoperative malignant glioma (Baseline PET scans).
- Resolution of all acute toxic effects of prior therapy to grade ≤ 1 (except alopecia)
- Patients must have an ECOG performance status of 0-2
- Patients must be ≥ 18 years and ≤ 80 years of age, with a life expectancy of greater than 8 weeks
Patients must have adequate organ function as defined by the following criteria:
Bone Marrow Reserve
- Platelets ≥ 75.000/μL
- Absolute Neutrophil Count ≥ 1500/μL
- Hemoglobin ≥ 10.0 g/dL Blood Coagulation
- aPTT ≤ 1.5 times upper limit of normal (ULN) Hepatic Function
- ASAT and ALAT ≤ 2.5 times ULN
- ALP ≤ 2.5 times ULN
- Total SERUM Bilirubin < 1.5 times ULN Renal Function
- SERUM Creatinine ≤ 1.5 times ULN Metabolism
- SERUM Albumin ≥ 3.0 g/dL All tests must be performed ≤ 3 days prior to study enrollment. Eligibility for hemoglobin count may be reached by transfusion.
- Signed and dated informed consent document by the patient, indicating that the patient has been informed of all the pertinent aspects of the trial prior to study enrollment.
Willingness and ability of the patient to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.
Exclusion Criteria:
- The patient is active participant in another clinical trial, which investigates substances with antiangiogenic effectiveness
Exclusion of patients in the event of
- surgery of a recurrent / progressed malignant glioma within 2 weeks prior to study enrollment
- chemotherapy (Standard therapy o Second Line Chemotherapy) within 2 weeks prior to study enrollment
- radiation therapy (Standard therapy) within4 weeks to study enrollment
- evidence in baseline MRI of intratumoral or peritumoral hemorrhage deemed clinically significant by the treating physician (area of hemorrhage > 25% of tumor area)
Significant Co-Morbidities within 12 months prior to study enrollment
- myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft, congestive heart failure
- cerebrovascular accident including transient ischemic attack
Significant Co-Morbidities at Baseline Evaluation
- Hypertension that cannot be controlled by medications (>150/100 mmHg despite optimal medical therapy)
- Pulmonary embolism within 4 weeks before study enrollment
- A known HIV (human immunodeficiency virus) or Hepatitis B/C infection or severe acute infection
- Anticoagulation: Current treatment with therapeutic doses of Marcoumar / Sintrom excluding thrombosis prophylaxis with low dose Heparin
Pregnancy, Breastfeeding and Non-Contraception
- Female patients who are pregnant or nursing
- Patients who are sexually active and unwilling or unable to use a medically acceptable method of contraception during the trial
Evidence of increased intracranial pressure
- midline shift > 5 mm
- headache, distinct nausea and vomiting
- Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that would impart excess risk associated with study participation or study drug administration, or which would make the patient inappropriate for entry into this study. The decision to enroll the patient in this study is in the judgment of the investigator.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Diagnose
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
---|---|
To determine the objective tumor response criteria (RR, ORR, ORD) assessed by Standard MRI and FET-/FLT-PET during Avastin / Irinotecan chemotherapy.
Zeitfenster: three years
|
three years
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
---|---|
Evaluation of the predictive / prognostic value of the VEGF pathway and tumor cell proliferation rate in tumor and vascular cells of malignant gliomas treated with Avastin / Irinotecan Chemotherapy
Zeitfenster: three years
|
three years
|
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Ermittler
- Hauptermittler: Guenther Stockhammer, MD, Prof., Department for Neurology, Medical University Innsbruck
Publikationen und hilfreiche Links
Nützliche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Voraussichtlich)
Studienabschluss (Voraussichtlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Pathologische Prozesse
- Neubildungen nach histologischem Typ
- Neubildungen
- Neubildungen, Drüsen und Epithelien
- Krankheitsattribute
- Neubildungen, Neuroepithel
- Neuroektodermale Tumoren
- Neoplasmen, Keimzelle und Embryonal
- Neubildungen, Nervengewebe
- Wiederauftreten
- Gliom
- Physiologische Wirkungen von Arzneimitteln
- Molekulare Mechanismen der pharmakologischen Wirkung
- Enzym-Inhibitoren
- Antineoplastische Mittel
- Topoisomerase-Inhibitoren
- Antineoplastische Mittel, immunologische
- Angiogenese-Inhibitoren
- Angiogenese-modulierende Mittel
- Wuchsstoffe
- Wachstumshemmer
- Topoisomerase I-Inhibitoren
- Bevacizumab
- Irinotecan
Andere Studien-ID-Nummern
- EUDRACT-Nr: 2009-015036-15
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Bevacizumab / Irinotecan
-
GERCOR - Multidisciplinary Oncology Cooperative...Hoffmann-La RocheAktiv, nicht rekrutierendDarmkrebs metastasiertIrland, Frankreich, Israel
-
Northwestern UniversityNational Cancer Institute (NCI); Ipsen BiopharmaceuticalsAbgeschlossenRezidivierendes Eileiterkarzinom | Rezidivierendes Ovarialkarzinom | Rezidivierendes primäres Peritonealkarzinom | Platinresistentes Eileiterkarzinom | Platinresistentes primäres Peritonealkarzinom | Platinresistentes Ovarialkarzinom | Refraktäres Ovarialkarzinom | Refraktäres Eileiterkarzinom | Refraktäres...Vereinigte Staaten
-
Johns Hopkins All Children's HospitalThe V Foundation; Brain Tumor AllianceAbgeschlossenTumore des zentralen NervensystemsVereinigte Staaten
-
Cancer Institute and Hospital, Chinese Academy...RekrutierungMetastasierter DarmkrebsChina
-
Taiho Pharmaceutical Co., Ltd.Abgeschlossen
-
Cancer Institute and Hospital, Chinese Academy...UnbekanntDarmkrebs | Metastasierender Krebs | Kolorektales AdenokarzinomChina
-
PfizerAbgeschlossenKolorektale NeubildungenAustralien, Kanada, Vereinigte Staaten, Neuseeland
-
Clinical Research Center for Solid Tumor, KoreaSeoul National University HospitalAbgeschlossenGlioblastom | AstrozytomKorea, Republik von
-
Ruijin HospitalRekrutierungRezidivierendes GlioblastomChina
-
Ulrik LassenAbgeschlossen